Driver Mark, Upadhyay Urmen D, Shapshay Stanley M, Wang Zhi
Department of Otolaryngology-Head and Neck Surgery, Boston University School of Medicine, Boston, Massachusetts, USA.
Laryngoscope. 2005 Feb;115(2):283-6. doi: 10.1097/01.mlg.0000154734.54152.9a.
Systemic retinoic acid (RA) treatment for chemoprevention of squamous cell carcinoma of the head and neck (HNSCC) is limited by RA's toxic side effects at therapeutic doses. The pulsed-dye laser (PDL), through a mechanism of selective vascular targeting, may allow reduction of the RA dose to one that is better tolerated when these treatments are used in combination. This study tests our hypothesis that combination therapy of PDL irradiation and low-dose systemic RA is as effective as high-dose RA therapy alone in the chemoprevention of HNSCC.
Randomized, prospective study in a hamster model.
Dysplastic lesions were induced in the cheek pouches of 48 hamsters by painting with topical 9,10-dimethl-1,2-benzanthrancene (DMBA). The hamsters were randomly divided into four treatment groups: 1) control (no treatment); 2) PDL irradiation only; 3) 5.0 mg RA (all-trans retinoid, 5.0 mg/kg per day, intraperitoneally [IP]); and (4) PDL + 0.5 mg RA (0.5 mg/kg per day, IP). The PDL irradiation was conducted at day 0 and 15, whereas the RA treatment was continued for 27 days. Tumor burden was measured over time.
The lesions in all of three treatment groups grow more slowly than the untreated controls. The combination treatment of PDL and RA had the greatest inhibitory effect on tumors.
This study suggests that combination treatment of PDL and low-dose RA is more effective than high-dose RA alone in the chemoprevention of HNSCC in a hamster cheek-pouch model, so that it should allow greatly improved tolerance of this regimen.
全身用维甲酸(RA)对头颈部鳞状细胞癌(HNSCC)进行化学预防的治疗受到治疗剂量下RA毒性副作用的限制。脉冲染料激光(PDL)通过选择性血管靶向机制,可能使RA剂量降低到联合使用这些治疗方法时耐受性更好的水平。本研究检验我们的假设,即PDL照射与低剂量全身RA联合治疗在HNSCC化学预防中与单独高剂量RA治疗一样有效。
在仓鼠模型中进行的随机、前瞻性研究。
通过局部涂抹9,10-二甲基-1,2-苯并蒽(DMBA)在48只仓鼠的颊囊中诱导发育异常病变。仓鼠被随机分为四个治疗组:1)对照组(不治疗);2)仅PDL照射;3)5.0 mg RA(全反式维甲酸,每天5.0 mg/kg,腹腔内注射[IP]);以及(4)PDL + 0.5 mg RA(每天0.5 mg/kg,IP)。在第0天和第15天进行PDL照射,而RA治疗持续27天。随时间测量肿瘤负荷。
所有三个治疗组中的病变生长均比未治疗的对照组缓慢。PDL和RA联合治疗对肿瘤的抑制作用最大。
本研究表明,在仓鼠颊囊模型中,PDL与低剂量RA联合治疗在HNSCC化学预防中比单独高剂量RA更有效,因此应能大大提高该方案的耐受性。